IFP Advisors’s Protalix BioTherapeutics PLX Stock Holding History

IFP Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21	Buy	9 +6	+200%	+$13	﹤0.01%	5067
2026 Q1	$7	Buy	+3	New	+$7	﹤0.01%	4981

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

IFP Advisors's PLX Position: Q2 2026 in Review

IFP Advisors increased its Protalix BioTherapeutics (PLX) stake by 200% in Q2 2026, buying an estimated $13 and bringing the position to 9 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #5067.

IFP Advisors first reported a position in PLX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

IFP Advisors held 9 shares of Protalix BioTherapeutics worth $21 as of Q2 2026.
IFP Advisors bought 6 Protalix BioTherapeutics shares in Q2 2026, an estimated $13.
Protalix BioTherapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5067 holding.
IFP Advisors first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 2 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.